Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $7.50 (from $6.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)